Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of subcutaneous MSB0010841 in healthy male volunteers
NL-OMON38778Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Feb 2013
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease, rheumatoid arthritis (RA) and psoriasis comparing MSB0010841 single ascending dose with Placebo (2 arms). Primary endpoints: Pharmacodynamic parameters, Pharmacokinetic parameters and 2 more. Started Feb 2013; status: active, not recruiting.
02
Drugs
sonelokimab
03
Conditions
autoimmune diseaserheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NL-OMON38778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38778.